AVI Biopharma

Company:	AVI Biopharma
Web Site:	http://www.antivirals.com
Purchase Price:	$1.16
Current Price:	Click Here

AVI Biopharma has been on my watch list for several months, since their acquisition of Ercole Biotech earlier this year. The company has been increasing its revenues, but like so many other small fish that try to absorb another small fish, the expenses it took on in the acquisition have weighed down its balance sheet with debt.

In recent months, the company has been refocusing its portfolio of projects with an eye toward routing resources to the most promising research and have brought aboard industry heavyweight J. David Boyle as their CFO. I have the sense that this transfusion could bring life back to the company, whose stock has been on a slow and steady decline thus far.